|
|
1. MARKET OVERVIEW
|
Influencer Market Insights |
World Market Trajectories |
Duchenne Muscular Dystrophy (DMD) Drugs Market To Exhibit Strong Growth |
Duchenne Muscular Dystrophy Drugs – Global Key Competitors Percentage Market Share in 2023 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 46 Players Worldwide in 2023 (E) |
Impact of Covid-19 and a Looming Global Recession |
Global Market Dynamics
|
Treatment Overview and Recent Developments
|
Steroids used for the Treatment of DMD
|
Translarna Exhibits Positive Result in Children with DMD
|
Clinical Trials Depict Emflaza Preserves Motor Function Better than Corticosteroids
|
Trial Shows Golodirsen Increases Dystrophin Production in DMD Patients
|
Casimersen and Golodirsen Exhibits Positive Results in Sarepta’s ESSENCE study
|
EXONDYS 51® Drug Details
|
FDA Approves Corticosteroid Emflaza for Treating DMD Patients
|
2. FOCUS ON SELECT PLAYERS
|
3. MARKET TRENDS & DRIVERS
|
Pipeline Analysis |
Drug Price Details: Exondys51 |
Sarepta’s DMD Gene Therapy Trial Update
|
4. GLOBAL MARKET PERSPECTIVE
|
World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Mutation Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Mutation Suppression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Exon Skipping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Duchenne Muscular Dystrophy Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Steroid Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
|
UNITED STATES
|
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
CANADA
|
Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
JAPAN
|
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
CHINA
|
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
EUROPE
|
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Irish Boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) Gains Access to Key, Life-Supporting Drug |
CHMP Rejects Exondys 51 in Europe |
Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
FRANCE
|
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
GERMANY
|
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
ITALY
|
Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
UNITED KINGDOM
|
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
REST OF EUROPE
|
Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
ASIA-PACIFIC
|
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
REST OF WORLD
|
Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for Duchenne Muscular Dystrophy Drugs by Segment - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy, Mutation Suppression and Other Segments for the Years 2023 & 2030 |
|
|